Why the study?
Residual thrombosis risk causes ischemic events after PCI for ACS, but individualized treatment with low-dose rivaroxaban based on risk stratification remains rare.
Does a 3-month course of low-dose rivaroxaban added to DAPT reduce MACCE in ACS patients undergoing PCI who have a high PARIS coronary thrombosis score and elevated D-dimer?
Does a 3-month course of low-dose rivaroxaban added to DAPT reduce MACCE in ACS patients undergoing PCI who have a high PARIS coronary thrombosis score and elevated D-dimer?
The PRIDE-ACS trial will determine if a biomarker- and risk score-guided strategy of short-term (3-month) low-dose rivaroxaban added to DAPT improves ischemic outcomes without unacceptable bleeding in high-risk ACS patients post-PCI.
Answers are grounded in this paper and cite their sources.
May guide personalized short-term rivaroxaban in high-risk post-PCI ACS; extends dual-pathway inhibition evidence via biomarker-risk stratification.
Background Residual thrombosis risk is an important contributor to ischemic events in patients with Acute Coronary Syndrome (ACS) after Percutaneous Coronary Intervention (PCI). Although previous studies have shown that rivaroxaban 2.5mg twice daily in ACS patients with high ischemic risk can significantly reduce the risk of ischemic recurrence and mortality, individualized treatment with low-dose rivaroxaban is still rare. Aim Using D-dimer and PARIS coronary thrombosis risk score to identify ACS patients at high ischemic risk, we aim to investigate whether 3-month low-dose rivaroxaban therapy on the basis of dual antiplatelet therapy (DAPT) could result in reduced ischemic events without increasing bleeding. Design This study is a multi-center, prospective, open-label, randomized controlled trial involving 3,944 ACS patients undergoing PCI from more than 40 tertiary hospitals in China ( ClinicalTrials.gov NCT05638867 ). Patients with PARIS coronary thrombosis score ≥ 3 and D-dimer ≥ 0.28μg/ml will be 1:1 randomized to experiment group (rivaroxaban 2.5mg twice daily for 3 months on the basis of one-year standard DAPT) or control group (one-year standard DAPT only). The primary endpoint of this study was Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), a composite of death, myocardial infarction, ischemia driven revascularization, stent thrombosis and systemic embolic events. The safety endpoint was BARC type 3 and 5 bleeding events. Summary In ACS patients with higher PARIS coronary thrombosis risk score and elevated D-dimer level, results of the PRIDE-ACS trial will reveal whether short-duration low-dose rivaroxaban can reduce MACCE events without increasing severe bleeding.
No takes yet. Share an insight, caveat, or question.
Jia et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: